bearish
Viva Biotech (维亚生物) IPO: When CRO Becomes Early Stage Biotech Investor
1.4k Views03 Jan 2019 13:32
Viva Biotechnology, a China-based drug discovery company, is seeking to raise USD 200m to list on the Hong Kong Stock Exchange. In this insight, we...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 9-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (6 April 2019) - Bilibili, Huya, Qutoutiao, Polycab, PNB Metlife, CIMC Vehicle06 Apr 2019
- ECM Weekly (30 March 2019) - ESR, Yunji, Ruhnn, Jinxin Fertility, Metropolis Health, Viva Biotech30 Mar 2019
- Viva Biotech (维亚生物) IPO: Warning Signs from 2018 Numbers (Part 2)28 Mar 2019
- WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different20 Nov 2018
- Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect05 Nov 2018
x